Rotational thromboelastometry versus conventional tests in decompensated cirrhotic children undergoing invasive procedures.

J Pediatr Gastroenterol NutrJun 3, 2026 (epub)
Clinical ResearchGastroenterologyPediatricsOpen access

Snigdha Verma, Bikrant Bihari Lal, Rajeev Khanna et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial evaluated the efficacy of a ROTEM-guided transfusion strategy in children aged 6 months to 18 years with decompensated cirrhosis undergoing invasive procedures. The study found that 76.3% of patients in the ROTEM group received blood component transfusions compared to 100% in the conventional group (p=0.001), indicating reduced transfusion exposure.

Key findings

  • 76.3% of patients in the ROTEM group received blood transfusions compared to 100% in the conventional group (p=0.001).
  • The volume of total and individual blood components transfused was comparable between the ROTEM and conventional groups.
  • There were no differences in procedure-related bleeding or transfusion-related complications between the two arms.
  • Total costs incurred were higher in the ROTEM group (p<0.001).

Why it matters

This study highlights the potential for ROTEM-guided transfusion strategies to reduce the need for blood component transfusions in pediatric patients with severe coagulopathy, which may influence transfusion practices in similar clinical scenarios.

Source

PubMed · PMID 42233422Free full text on PubMed Central

Published in J Pediatr Gastroenterol Nutr. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.